Scientific Reports · 2014 · 141 citations · 37 references
Life SciencesImmunologyPharmacotherapyImmunoregulationInflammationInnate ImmunityAntiviral ImmunityInnate Immune ActivationInnate Immune ModulationInnate Immune ResponseInterferon ResponsesViral InfectionsAdjuvant UseAnti-viral ImmunityInterferon Response To Viral InfectionIntranasal AdministrationRespiratory Viral InfectionsRespiratory VirusesRhinovirus InfectionVirus Replication Inhibition
Glucocorticosteroids (GCS) are used on a daily basis to reduce airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). This treatment is usually escalated during acute disease exacerbations, events often associated with virus infections. We examined the impact of GCS on anti-viral defences and virus replication and assessed supplementary interferon (IFN) treatment. Here, we report that treatment of primary human airway cells in vitro with GCS prior to rhinovirus (RV) or influenza A virus (IAV) infection significantly reduces the expression of innate anti-viral genes and increases viral replication. Mice given intranasal treatment with GCS prior to IAV infection developed more severe disease associated with amplified virus replication and elevated inflammation in the airways. Adjuvant IFN treatment markedly reduced GCS-amplified infections in human airway cells and in mouse lung. This study demonstrates that GCS cause an extrinsic compromise in anti-viral defences, enhancing respiratory virus infections and provides a rationale for adjuvant IFN treatment.
37
Role of deficient type III interferon-λ production in asthma exacerbations
Marco Contoli, Simon Message, Vasile Laza‐Stanca et al. · Nature Medicine · 2006 · 1K citations
Inhaled corticosteroids in COPD and the risk of serious pneumonia
Samy Suissa, Valérie Patenaude, Francesco Lapi et al. · Thorax · 2013 · 447 citations · Full text
Philip L. Molyneaux, Patrick Mallia, Michael J. Cox et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 401 citations · Full text